NCT01986569已完成3 期
A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 1
- 主要终点
- lesion-level positive and negative percent agreement between qualitative [18F]FES PET interpretation and reference IHC testing
研究概览
简要总结
The standard diagnostic workup for recurrent or metastatic breast cancer includes biopsy and determination of tumor estrogen status according to National Comprehensive Cancer Network and European Society for Medical Oncology. Immunohistochemistry (IHC) is currently the most commonly used method for determining ER status. A investigational imaging tracer named 16-alpha-[18F]-fluoro-17-beta-estradiol, or [18F]fluoroestradiol ([18F]FES) acts similarly in vivo to estradiol and binds to estrogen receptors (ERs). Previous studies in human have shown the efficacy of [18F]FES PET in detecting ER positive breast cancer without any observed toxicity. The investigators hypothesized that [18F]FES PET imaging can noninvasively assess ER status in recurrent or metastatic breast cancer lesion . In this study, a positive and negative percent agreement between IHC and [18F]FES will be determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient will be enrolled if the patient meets the following inclusion criteria
- •Patient is ≥19 years of age and male or female of any race/ethnicity
- •Patients has first recurrence or stage IV disease by American Joint Committee on Cancer tumor-node-metastasis staging system for breast cancer
- •Patients had histologically confirmed invasive primary breast carcinoma and the documented results of histology are available.
- •Patients are scheduled to undergo core needle biopsy or surgery for histological confirmation and determination of ER status of recurrent or distant metastatic cancer within 15 days after [18F]FES PET; or patients already underwent core needle biopsy of recurrent or distant metastatic cancer within 30 days before [18F]FES PET and biopsy specimens are available for determination of ER status.
- •Discontinuation of selective ER blocking agents including tamoxifen or fulvestrant for at least 60 days prior to [18F]FES PET
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
排除标准
- •A patient will be excluded from this study if the patient does not full fulfill the inclusion criteria, or if any of the following conditions are observed
- •Patient or patient's legally acceptable representative do not provide written informed consent
- •The recurrent or metastatic lesion scheduled to undergo biopsy is located in breast, liver, ovary, uterus, or bone
- •Female patient is pregnant or nursing. Exclusion of the possibility of pregnancy is made by one of the following: 1) woman is physiologically post menopausal (cessation of menses for more than 2 years), 2) woman is surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy, or 3) if the woman is of childbearing potential, a urine pregnancy test performed within 24 hours immediately prior to administration of [18F]FES has to be negative and the women is advised to apply contraceptive measures during her participation in this study
- •Adjuvant chemotherapy within 3 weeks prior to [18F]FES PET.
- •Radiation therapy or immuno/biologic therapy is scheduled to be given to patient before the histologic confirmation by biopsy or [18F]FES PET.
- •Concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer (e.g. congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic renal or hepatic disease which could compromise participation in the study) in the judgment of the investigator.
- •Patient is a relative of the investigator, student of the investigator or otherwise dependent
- •Patient has any other condition or personal circumstances that, in the judgment of the investigator, might interfere with the collection of complete data
- •Patient has been involved in an investigative, radioactive research procedure within 7 days prior to registration
研究组 & 干预措施
[18F]fluoroestradiol (FES)
Experimental
The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
干预措施: [18F]fluoroestradiol (FES) (Drug)
结局指标
主要结局
lesion-level positive and negative percent agreement between qualitative [18F]FES PET interpretation and reference IHC testing
时间窗: up to 3 years
次要结局
未报告次要终点
研究者
Dae Hyuk Moon
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Expanded Access Study of Talimogene Laherparepvec of Subjects in Europe with late stage MelanomaEUCTR2014-002834-30-ATAmgen Inc.11
进行中（未招募）
1 期
Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV with virologic suppressioCTIS2022-503137-66-00Viiv Healthcare UK Limited200
进行中（未招募）
1 期
A PHASE III, OPEN-LABEL, MULTICENTRIC CLINICAL TRIAL OF A SINGLE ARM OF 16 LENGTHS OF TIME TO EVALUATE RETENTION WITH ELBASVIR / GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C CHRONIC GENOTYPES 1.4 WHO HAVE FAILED TO TREAT WITH A REGIME BASED ON AN INHIBITOR OF THE NS5AEUCTR2017-000432-34-ESFundación SEIMC-GESIDA
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukaemia.Chronic lymphocytic leukaemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000087-29-IEF. Hoffmann- La Roche Ltd.950
进行中（未招募）
1 期
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)Advanced Biliary Tract CancersMedDRA version: 20.0Level: LLTClassification code: 10004676Term: Biliary tract disease Class: 10019805CTIS2022-502043-35-00AstraZeneca AB200